Literature DB >> 9725784

Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt.

D Azoulay1, D Castaing, A Lemoine, D Samuel, P Majno, M Reynes, B Charpentier, H Bismuth.   

Abstract

Azathioprine-induced veno-occlusive disease of the liver mainly described after kidney transplantation is as rare as severe with a high mortality due to acute portal hypertension and liver failure. A kidney-transplanted patient with severe azathioprine-induced veno-occlusive disease of the liver and worsening despite drug discontinuation was treated by emergency transjugular intrahepatic portosystemic shunt. Whereas the veno-occlusive disease was controlled, the patient developed severe intractable portosystemic encephalopathy successfully treated by a stent reducer maintaining a certain degree of portal diversion. Twelve months after transjugular intrahepatic portosystemic shunt, liver function was normalized and the stent was thrombosed with a subnormal liver histology. Thirty-six months after transjugular intrahepatic portosystemic shunt the patient is alive with normal liver function tests and kidney graft function. Transjugular intrahepatic portosystemic shunt for treatment of severe veno-occlusive disease of the liver is an alternative to tide the patient over until recovery of liver function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725784

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Reversible sinusoidal obstruction syndrome associated with tacrolimus following liver transplantation.

Authors:  Tian Shen; Xiao-Wen Feng; Lei Geng; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 2.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

3.  Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis.

Authors:  Zai-Bo Jiang; Hong Shan; Xin-Ying Shen; Ming-Sheng Huang; Zheng-Ran Li; Kang-Shun Zhu; Shou-Hai Guan
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.